FibrolexTechnologies
A Trail blazing Biotech Startup established to advance exclusive, Self-Targeting Inhibitor of Fibrosis as first in class antifibrotic therapeutic.
A Trail blazing Biotech Startup established to advance exclusive, Self-Targeting Inhibitor of Fibrosis as first in class antifibrotic therapeutic.
We aim to capture the multi-billion-dollar market bydelivering high-impact Inhibitors that target profibrotic cells. We aretransforming unique scientific discoveries into therapeutic breakthroughs thatdrive progress towards combating fibrosis.
Led by Dr. Branko Stefanovic, FibrolexTech creates therapies targeting profibrotic cells specifically. Our proprietary approach tackles the root causes of scarring directly, avoiding the toxicity of less selective treatments.
Our mechanism utilizes a self-targeting molecule that zeros in on profibrotic cells effectively halting excessive collagen production at its specific source.
This precise method ensures only profibrotic cells aretargeted, providing a superior safety profile and high efficacy.
Unlike systemic drugs, our designer drug targets profibrotic cells to deactivate the active pathways driving organ scar formation.
Suppression of fibrosis in human organoids after treatment with the Fibrolex Technologies inhibitor.Treatment of Organ Fibrosis becomes reality.
